Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;30(4):1366-1375.
doi: 10.1007/s43032-022-01033-7. Epub 2022 Aug 8.

Pressure-Induced Fibroid Ischemia: First-In-Human Experience with a Novel Device for Laparoscopic Treatment of Symptomatic Uterine Fibroids

Affiliations

Pressure-Induced Fibroid Ischemia: First-In-Human Experience with a Novel Device for Laparoscopic Treatment of Symptomatic Uterine Fibroids

Michael G Tal et al. Reprod Sci. 2023 Apr.

Abstract

The purpose of this study was to assess the feasibility of use of a novel uterine fibroid treatment device hypothesized to cause fibroid infarction by increasing intra-tumoral pressure. Between August 2019 and January 2020, 21 uterine fibroids were treated in 16 symptomatic pre-menopausal black women. Pelvic magnetic resonance imaging was performed before the procedure, a day after the procedure and at 1, 3, 6, and 12 months. The subjects were also followed for clinical outcomes and quality of life up to 12 months at a single investigational site. At 3 months, the mean reduction in the fibroid volume was 36.3% (P = .002). Incremental reduction in volume peaked at the end of the follow-up, at the 12-month mark (60.4%; P = .008). There were no procedures in which the users failed to perform laparoscopic pressure suturing of fibroids with the pressure-induced fibroid ischemia device. Improvement in the quality of life was evident in the Health-Related Quality of Life total, Energy/Mood, Control, and Sexual Function domains of the Uterine Fibroid Symptom and Quality of Life questionnaire at 3 months post-procedure. Unanticipated risks were not identified. Serious adverse events were not identified. The initial clinical assessment of the pressure-induced fibroid ischemia device supports feasibility of the approach and does not reveal serious safety concerns. Trial is currently being registered retrospectively (This was a feasibility study and therefore registration was not mandatory).

Keywords: Fibroid; Ischemia; Pressure; Suturing.

PubMed Disclaimer

Conflict of interest statement

MG Tal, R Keidar, G Magnazi, O Henn, and KJ Stepp declared having equity in Empress Medical, which developed and manufactured the Empress Fibroid Treatment System.

Figures

Fig. 1
Fig. 1
Illustration of a the PIFI system and b the mechanism of the treatment action
Fig. 2
Fig. 2
Consolidated Standards of Reporting Trials (CONSORT) flow diagram
Fig. 3
Fig. 3
MRI—gadolinium-enhanced fat-suppressed T1-weighted images of a uterine fibroid a before the treatment—arrows point to the treated fibroid; b 12 months after the treatment; c 1 day after the treatment—arrows mark the sites at which sutures were placed with the PIFI system

References

    1. Hartmann KE, et al. Management of uterine fibroids. AHRQ Comp Eff Rev. 2017; Rockville (MD): Agency for Healthcare Research and Quality (US).
    1. Ponomarenko I, et al. Candidate genes for age at menarche are associated with uterine leiomyoma. Front Genet. 2020;11:512940. doi: 10.3389/fgene.2020.512940. - DOI - PMC - PubMed
    1. Boosz AS, et al. The conservative and interventional treatment of fibroids. Dtsch Arztebl Int. 2014;111(51–52):877–883. - PMC - PubMed
    1. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect. 2003;111(8):1037–1054. doi: 10.1289/ehp.5787. - DOI - PMC - PubMed
    1. Baird DD, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100–107. doi: 10.1067/mob.2003.99. - DOI - PubMed

Publication types